Ten of the biggest pharmaceutical businesses in the world have joined forces to improve drug development outcomes. Although they claim to be fierce competitors, they say that they need to share resources and experience to reduce the costs of bringing new drugs to market, deal with clinical drug development problems and maximise patient outcomes. The ten companies forming the TransCelerate group are Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche and Sanofi. The projects that they will be undertaking include developing a shared user interface for investigator site portals and clinical data standards. TransCelerate will be based in Philadelphia and hopes that other pharma businesses will join in. The US Food and Drug Administration and the European Medicines Agency have reacted positively to the initiative.